A First in Human (FIH) single ascending dose Phase 1 study of ZKN-013 for the potential treatment of recessive dystrophic epidermolysis bullosa (RDEB)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

12 Nov 2024 According to an Eloxx Pharmaceuticals media release, USFDA has allowed continued dosing of subjects in Phase 1 trial of ZKN-013, following successful dosing of the initial subjects. Eloxx is awaiting confirmation from Almirall, who has global rights to develop and commercialize ZKN-013, to proceed with the study based on their review of the results and FDA feedback.
11 Jul 2024 According to an Eloxx Pharmaceuticals media release, first two subjects have been dosed in this trial.
11 Jul 2024 Status changed from planning to recruiting as per Eloxx Pharmaceuticals media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com